U.S. Medicine Magazine features CyPath Lung, citing potential $895M savings and 92% sensitivity

bioAffinity Technologies, Inc.

CyPath Lung featured in U.S. Medicine pulmonary issue, highlighting improved lung cancer detection for veterans.
Economic modeling shows up to $895M savings for private payers, $379M for Medicare if used in 2022 standard of care.
Clinical performance: 92% sensitivity, 87% specificity, 88% accuracy in nodules ≤20 mm.
Case studies report Stage 1A detection when PET/CT, serum markers, and risk models failed.
Study authored by BAMC and VA pulmonologists, supporting integration into VA standard of care.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.